Results 191 to 200 of about 100,848 (298)

Producer perspectives on the constraints to aquaculture development in the US Great Lakes region. [PDF]

PLoS One
Hartenstine HA, Carlton JS.
europepmc   +1 more source

Cost‐utility analysis of nusinersen–risdiplam switch in patients with spinal muscular atrophy in Croatia: A discrete event simulation model

British Journal of Clinical Pharmacology, EarlyView.
Introduction In recent years, the treatment of spinal muscular atrophy (SMA), a rare disease, has significantly progressed, improving patients' survival and overall quality of life. However, current SMA treatments are expensive, and some (nusinersen) are very inconvenient for patients.
Andrej Belančić, Ivana Stević, Elvira Meni Maria Gkrinia, Dinko Vitezić, Slobodan Janković   +4 more
wiley   +1 more source

Site-Engineered Corundum-Structured Aesthetic Composites for Alleviating Heat Accumulation to Mitigate Urban Heat Islands. [PDF]

Small
Darshan GP, Arjun A, Mishra S, Singh AK, Vomiero A, Moretti E.   +5 more
europepmc   +1 more source

Empirical analysis of the correlation between China's Macroeconomic Market and Crude Oil Market based on mixed-frequency group factor model. [PDF]

PLoS One
Zhao J, Yin J.
europepmc   +1 more source

How the HTAR will contribute to a value‐based decision‐making for medicinal products across the EU

British Journal of Clinical Pharmacology, EarlyView.
The European Union Health Technology Regulation 2021/2282 (HTAR) introduces joint assessment of health technologies (including medicinal products and medical devices) across EU Member States. It was signed into law in 2021 and came into full force in January 2025.
Roisin Adams, Michal Stanak
wiley   +1 more source

Smartphone Apps for Cannabis Cessation: Quality Assessment and Content Analysis. [PDF]

JMIR Mhealth Uhealth
Seth S, Kushwaha S, Prashad R, Chaiton M.   +3 more
europepmc   +1 more source

Beyond the label: Rethinking off‐label drug use in paediatrics. Towards a scientifically grounded and safer future for paediatric pharmacotherapy

British Journal of Clinical Pharmacology, EarlyView.
Abstract Despite regulatory progress being made in the past two decades, off‐label drug use in paediatrics remains pervasive, with prevalence estimated between 3% and 97% of prescriptions across different clinical settings. Off‐label use—defined as prescribing outside the conditions described in the Summary of Product Characteristics (SmPC)—is often ...
Tjitske M. van der Zanden, Miriam G. Mooij, Matthijs de Hoog, Saskia N. de Wildt   +3 more
wiley   +1 more source

Enrollment Assister Perspectives of a Private Health Insurance Program for Undocumented Immigrants.

JAMA Health Forum
Welles CC, Rodriguez MF, Glaros C, Boggs E, Peters R, Schwartz N, Dorsey B, Cervantes L.   +7 more
europepmc   +1 more source

Characterising concerns and misinformation shaping global HIV vaccine confidence and demand: a structured literature search and content analysis. [PDF]

BMJ Glob Health
Bokolo S, Rabin M, Penuela-Wermers S, Chetty-Makkan CM, Egbe TI, Thirumurthy H, Maughan-Brown B, Buttenheim A.   +7 more
europepmc   +1 more source

Zuranolone: A case study in (regulatory) rush to judgement?

British Journal of Clinical Pharmacology, EarlyView.
Abstract Sage, in collaboration with Biogen, submitted a new drug approval for zuranolone for postpartum depression (PPD) and major depressive disorder (MDD) in December 2022. In August 2023, the US Food and Drug Administration granted approval for PPD but denied approval for MDD.
Lisa Cosgrove, Milutin Kostic, Barbara Mintzes, Gianna D'Ambrozio, Allen Shaughnessy   +4 more
wiley   +1 more source